Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 11/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | MTOR | P42345 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656945 | 0.93 | PIK3CA (0.48) | PIK3CAPIK3CDPIK3R1HDAC1MTOR | |
| SCHEMBL11980067 | 0.93 | PIK3CA (0.50) | PIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL1656954 | 0.92 | PIK3CA (0.47) | PIK3CAPIK3CDPIK3R1HDAC1MTOR | |
| SCHEMBL11980024 | 0.91 | PIK3CA (0.45) | PIK3CAPIK3CDPIK3R1MTOR | |
| SCHEMBL11980094 | 0.91 | PIK3CA (0.47) | PIK3CAPIK3CDPIK3R1HDAC1MTOR | |
| SCHEMBL11980068 | 0.90 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3R1MTORPIK3CB | |
| SCHEMBL11980066 | 0.89 | PIK3CA (0.45) | PIK3CAPIK3CDPIK3R1HDAC1MTOR | |
| SCHEMBL11908757 | 0.86 | PIK3CA (0.49) | PIK3CAPIK3CDPIK3R1HDAC1MTOR | |
| SCHEMBL11980073 | 0.85 | PIK3CA (0.53) | PIK3CAPIK3CDPIK3R1HDAC1MTOR | |
| SCHEMBL11980022 | 0.84 | PIK3CA (0.49) | PIK3CAPIK3CDPIK3R1HDAC1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491036-B1 | 1,4-substituted 6-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidine derivatives as phosphoinositide-3-kinase inhibitors (PI3K) for treating allergies and asthma | MERCK PATENT GMBH (DE) | 2017-07-19 | — | — | EP | claimed |
| US-8741896-B2 | Pyrazolopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2014-06-03 | — | — | US | claimed |
| US-20120208808-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-08-16 | — | — | US | claimed |
| EP-2491036-B1 | 1,4-substituted 6-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidine derivatives as phosphoinositide-3-kinase inhibitors (PI3K) for treating allergies and asthma | MERCK PATENT GMBH (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-8741896-B2 | Pyrazolopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8741896-B2 | Pyrazolopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8741896-B2 | Pyrazolopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| EP-2491036-A2 | PYRAZOLOPYRIMIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-20120208808-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120208808-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-08-16 | — | — | US | disclosed |
| WO-2011047770-A2 | PYRAZOLOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011047770-A2 | PYRAZOLOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208808-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | PDPK1, PIK3R5, NLRP1 | PIK3CA 7/4885PIK3CD 15/4885PIK3R1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.